drugset / Trial / NCT07327840
Phase 2 Study of Kylo-11 in ASCVD Patients With Elevated Lp(a)
RandomizedParallel-groupDouble-blindTreatment
Summary
This is a phase 2, double-blind, randomized, placebo-controlled, multi-center, dose-finding study to evaluate the efficacy and safety of Kylo-11 administered subcutaneously compared to placebo in participants with ASCVD and elevated Lp(a).
Timeline
- Start
- 2025-10-29
- Primary completion
- 2027-02-28
- Completion
- 2028-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Kylo-11 | Unknown | — | Subcutaneous |